Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 1.33 thousand shares for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2026-03-31
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2013-12-31 was 929.00 shares, a 88.90% decline year-over-year.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2013-09-30 was 5.09K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2012-12-31 was 8.37K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2024 was 1.33K shares, a 566.50% increase from fiscal 2023.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2023 was 200.00 shares, a 100.00% increase from fiscal 2022.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2022 was 100.00 shares, a 51.52% increase from fiscal 2021.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2021 was 66.00 shares, a 71.67% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | 1.33K shares 10-K · filed 2026-03-31 | 20.00K shares 10-K · filed 2025-02-27 | |||
| 2023-12-31 | 200.00 shares 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | 100.00 shares 10-K · filed 2024-03-28 | ||||
| 2021-12-31 | 66.00 shares 10-K · filed 2023-03-30 | ||||
| 2020-12-31 | 233.00 shares 10-K · filed 2022-03-31 | 3.50K shares 10-K · filed 2021-03-19 | |||
| 2019-12-31 | 38.00K shares 10-K · filed 2021-03-19 | ||||
| 2013-12-31 | 929.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | 6.02K shares derived: sum of 2 quarters · filed 2016-03-30 | 1.85K shares 10-K · filed 2016-03-30 | -2.41K shares 10-K · filed 2014-03-13 | |
| 2013-09-30 | 5.09K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | 926.00 shares 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | -4.17K shares 10-Q · filed 2013-08-08 | ||||
| 2012-12-31 | 8.37K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | 1.70K shares 10-K · filed 2015-03-12 | -7.67K shares 10-K · filed 2013-03-18 | ||
| 2012-09-30 | -6.67K shares 10-Q · filed 2012-11-09 | ||||
| 2011-12-31 | -1.41K shares 10-K · filed 2014-03-13 | -6.33K shares 10-K · filed 2013-03-18 | |||
| 2010-12-31 | -22.17K shares 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |